Investing.com - Cogent Biosciences (NASDAQ: COGT) reported fourth quarter EPS of $-0.630, $0.07 worse than the analyst estimate of $-0.560. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Cogent Biosciences's stock price closed at $7.440. It is down -3.000% in the last 3 months and down -42.610% in the last 12 months.
Cogent Biosciences saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Cogent Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Cogent Biosciences's Financial Health score is "fair performance".
Check out Cogent Biosciences's recent earnings performance, and Cogent Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar